

051804

# UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No.

P32672C1

First Named Inventor

Craig et al.

(For new nonprovisional applications under 37 CFR 1.53(b))

**"EXPRESS MAIL CERTIFICATE"**EXPRESS MAIL MAILING LABEL NUMBER **EL964437102US** DATE OF DEPOSIT: **19 May 2004**

I hereby certify that this paper or fee and the papers indicated as being transmitted herewith are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date and with the Mailing Label Number indicated above and addressed to:  
COMMISSIONER FOR PATENTS, MAIL STOP: PATENT APPLICATION, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

NAME OF PERSON MAILING PAPER OR FEE

(TYPE OR PRINT)

Ceryl Thompson

SIGNATURE

[Signature]2278 U.S. PTO  
10/849603

051804

APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents.</i>	
1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. <u>19-2570</u> <input checked="" type="checkbox"/> General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3)) <i>(Submit an original, and a duplicate for fee processing)</i>	7. <input checked="" type="checkbox"/> The Title of the Invention: Sodium Salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
2. <input checked="" type="checkbox"/> The total fee is calculated as shown below: Basic Filing fee \$770.00 Total Claims 12 - 20 = 0 x \$18 \$ 0.00 Independent Claims 1 - 3 = 0 x \$86 \$ 0.00 <input type="checkbox"/> Multiple Dependent Claim present. \$290 <b>TOTAL FILING FEE \$770.00</b> <input checked="" type="checkbox"/> Cancel in this application original claims <u>13</u> to <u>14</u> of the prior application before calculating the filing fee. <input checked="" type="checkbox"/> Charge <b>\$770.00</b> to the above indicated Deposit Account.	8. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies d. <input type="checkbox"/> Use the identical computer-readable form filed in Application No. _____, filed _____ as the computer-readable form for the instant application. (37 CFR 1.821(e))
3a. <input checked="" type="checkbox"/> Specification excluding Drawings [Total Pages] <u>13</u> 3b. <input checked="" type="checkbox"/> Abstract on a separate sheet [Total Pages] <u>1</u>	9. <b>ACCOMPANYING APPLICATION PARTS</b> a. <input type="checkbox"/> Information Disclosure Statement (IDS) b. <input type="checkbox"/> PTO-1449 c. <input type="checkbox"/> Copies of all IDS Citations
4. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets] <u>4</u>	10. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))
5. <input checked="" type="checkbox"/> Declaration and Power of Attorney [Total Pages] <u>3</u> a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 17a completed)</i> c. <input type="checkbox"/> Unsigned Declaration <i>[Note Box 6 below]</i> i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	11. <input checked="" type="checkbox"/> Prior Application is Assigned to: <u>SmithKline Beecham p.l.c.</u> <i>(for continuation/divisional with Box 17a completed)</i>
6. <input checked="" type="checkbox"/> Incorporation By Reference <i>(useable if Box 5b is checked)</i> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	12. <input checked="" type="checkbox"/> Preliminary Amendment [Total Pages] <u>5</u>
	13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i>
	14. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i>
	15. <input checked="" type="checkbox"/> Transfer all references cited by Applicants or by the Examiner from the parent Application Serial No. <u>10/381,496</u> filed <u>July 15, 2003</u> . A PTO-1449 listing the references is enclosed.
	16. <input type="checkbox"/> Other: _____

17. <input checked="" type="checkbox"/> Priority Information, check appropriate box and supply the requisite information
a. The accompanying application is a <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: <u>10/381,496</u> filed <u>July 15, 2003</u> .
b. <input type="checkbox"/> Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications: Application No. _____ filed _____
c. <b>** Add claim to priority via Preliminary Amendment.</b>

Correspondence Address:	GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939	Signature Name	Respectfully Submitted, <u>Kathryn L. Sieburth</u> Kathryn L. Sieburth
Telephone	(610) 270-5012 Fax (610) 270-5090	Registration No.	40,072

20462

PATENT TRADEMARK OFFICE